317 related articles for article (PubMed ID: 21451123)
61. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
62. K-RasV14I recapitulates Noonan syndrome in mice.
Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213
[TBL] [Abstract][Full Text] [Related]
63. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
Romerio F; Riva A; Zella D
Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
[TBL] [Abstract][Full Text] [Related]
64. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Cheon SK; Kim HP; Park YL; Jang JE; Lim Y; Song SH; Han SW; Kim TY
Mol Oncol; 2018 Aug; 12(8):1398-1409. PubMed ID: 29896883
[TBL] [Abstract][Full Text] [Related]
65. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
66. Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Kiessling MK; Rogler G
Swiss Med Wkly; 2015; 145():w14207. PubMed ID: 26691679
[TBL] [Abstract][Full Text] [Related]
67. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.
Ranch D; Zhang MY; Portale AA; Perwad F
J Bone Miner Res; 2011 Aug; 26(8):1883-90. PubMed ID: 21472778
[TBL] [Abstract][Full Text] [Related]
68. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
[TBL] [Abstract][Full Text] [Related]
69. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
70. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
[TBL] [Abstract][Full Text] [Related]
71. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
72. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
73. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
74. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
[TBL] [Abstract][Full Text] [Related]
75. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
76. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
77. Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.
Anastasaki C; Rauen KA; Patton EE
Dis Model Mech; 2012 Jul; 5(4):546-52. PubMed ID: 22301711
[TBL] [Abstract][Full Text] [Related]
78. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
Van Meter ME; Díaz-Flores E; Archard JA; Passegué E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS
Blood; 2007 May; 109(9):3945-52. PubMed ID: 17192389
[TBL] [Abstract][Full Text] [Related]
79. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
80. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.
Peyssonnaux C; Provot S; Felder-Schmittbuhl MP; Calothy G; Eychène A
Mol Cell Biol; 2000 Oct; 20(19):7068-79. PubMed ID: 10982823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
